Results 81 to 90 of about 7,663 (213)

The effect of low-dose esketamine on maternal depression after cesarean delivery

Journal of Psychosomatic Obstetrics and Gynecology
Objective To assess the impact of low-dose intravenous esketamine on postpartum depression scores in women undergoing cesarean section.Methods In a randomized, double-blind, placebo-controlled trial, 186 women aged 20–50 years receiving epidural ...
Yan Shang, Siyuan Li, Qin Zheng, Tingting Mi, Yuzhu Lv, Lichun Han, Binrong Wang   +6 more
doaj   +1 more source

Exploring Molecular Mechanism of Fluoxetine in Animal Models of Depression via Integrated Metabolomic and Proteomic Analysis

Journal of Cellular and Molecular Medicine, Volume 30, Issue 6, March 2026.
ABSTRACT Fluoxetine is a widely used antidepressant, yet integrated analyses of its molecular mechanism remain limited. This study systematically investigated potential molecular mechanisms underlying the antidepressant effects of fluoxetine by integrating these scattered data. Using the ProMENDA database, we identified metabolites and proteins altered
Yin Chen, Wei Tang, Xiangkun Tao, Chi Liu, Hailin Wu, Ning Wang, Cenyu Liao, Nanxi He, Yiwen Chen, Yiyun Liu, Dongfang Wang, Siwen Gui, Xiaogang Zhong, Yuan Liu, Bin Hua, Lining Yang, Juncai Pu, Peng Xie   +17 more
wiley   +1 more source

Effect of pretreatment with low-dose Esketamine on the Propofol requirements and the onset time of cisatracurium during the induction of general anesthesia: a prospective, randomized, double-blinded trial

BMC Anesthesiology
Background Esketamine has been increasingly used as an adjuvant for propofol-based induction. However, the effective esketamine dose for this indication remains unclear.
Rui An, Chunnan Lin, Zeguang Lu, Wenqian Lin, Hongying Tan, Tianhua Zhang, Huiting Li, Longhui Cao   +7 more
doaj   +1 more source

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

Advanced Science, Volume 13, Issue 7, 3 February 2026.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang, Jiangang Xu, Xinyu Zhou, Lu Che, Minghan Qiu, Yang Liu, Ming Gao, Zhen Yang   +7 more
wiley   +1 more source

Ketamine for the treatment of major depression: a systematic review and meta-analysis

, 2023
Background: Intranasal esketamine has received regulatory approvals for the treatment of depression. Recently a large trial of repeated dose racemic ketamine also demonstrated efficacy in severe depression.
Bahji, A, Loo, C , Nikolin, S , Rodgers, A , Schwaab, A, Vazquez, G, Zarate, C   +6 more
core   +1 more source

Prefrontal neurophysiological changes associated with subanesthetic esketamine accelerating mice emergence from propofol anesthesia

Brain Research Bulletin
Background: Recent studies have demonstrated that subanesthetic dose of ketamine or its S-enantiomer, esketamine, can paradoxically accelerate the recovery of consciousness in rodents following general anesthesia.
Yinying Sun, Bo Li, Yiting Wang, Xuliang Jiang, Su Tang, Jiayi Zhang, Jun Zhang   +6 more
doaj   +1 more source

Efficacy and safety of esketamine for "treatment resistant depression": registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials [PDF]

Background: In 2019, the FDA and EMA approved intranasal esketamine for treatment-resistant depression (TRD). The current study re-evaluated its efficacy and safety. Methods: This registered report presents a systematic review and individual patient data
Barbui, Corrado, Cristea, Ioana A, Fodor, Liviu A, Gastaldon, Chiara, Le Pabic, Estelle, Naudet, Florian, Pellen, Claude, Turner, Erick H   +7 more
core   +1 more source

Safety and Efficacy of Adjunctive Esketamine vs. MAOIs in TRD in Adults [PDF]

, 2023
Background: Depression affects millions globally - Treatment-resistant depression (TRD) is defined as failure to respond to two antidepressant trials of adequate dose and duration Traditional Treatment for TRD: Switching or adding medications atypical ...
Guinan, Riley
core   +1 more source

Oral esketamine for difficult-to-treat depression [PDF]

Depressive disorder is a common mental health condition that causes significant personal suffering, functional limitations, loss of productivity, and high healthcare costs.
Smith-Apeldoorn, Sanne
core   +1 more source

Case report: two cases of rhabdomyolysis following esketamine treatment

Frontiers in Psychiatry
Major depressive disorder is a mental disorder affecting millions of people worldwide. A considerable proportion of patients demonstrate a lack of response to conventional treatment.
René Zeiss, Melissa Schweizer, Bernhard Connemann, Kathrin Malejko   +3 more
doaj   +1 more source